(2026). Comprehensive molecular profiling of advanced NSCLC in Greek patients:A prospective HeCOG study. Cancer Treatment and Research Communications, 48, 101310. https://doi.org/10.1016/j.ctarc.2026.101310
Περίληψη
BACKGROUND: We report for the first time the molecular landscape and outcome associations from the prospective CLIMEDIN trial in Greece. METHODS: Two hundred patients with newly diagnosed advanced NSCLC (March 2022-October 2023) were enrolled and randomized to standard-of-care education versus additional automated, adverse-event-targeted digital interventions. Within this study baseline testing (EGFR, ALK, PD-L1) was performed in all; 165 tumors underwent comprehensive NGS (Oncomine Comprehensive Assay v3). Primary endpoint was improvement in AEs/QoL; secondary endpoints included ORR, PFS and OS. Associations between genomic alterations and outcomes were explored. RESULTS: Median age was 68 years; 75% male; 52% current smokers; adenocarcinoma 68.5%. Most received chemo-immunotherapy (66%). At data cut-off (December 2025; reverse-Kaplan-Meier median follow-up 36.3 months), median PFS was 9.6 months and median OS was 15.2 months. Across 200 tumors, 495 pathogenic variants (PVs) were identified in 83 genes. Exploratory outcome analyses showed longer OS in EGFR-mutant disease (preserved under parsimonious multivariable adjustment) and a formal KRAS × smoking interaction for OS (interaction P = 0.011). CONCLUSIONS: In this cohort, the molecular profile mirrors other Caucasian series, with clinically relevant enrichment patterns for EGFR and KRAS. ECOG performance status and first line treatment were the dominant prognostic factors in this cohort. A novel KRAS and smoking interaction for overall survival warrants prospective validation.
- DOI
- 10.1016/j.ctarc.2026.101310
- Τύπος
- Άρθρο σε Περιοδικό
- Έτος
- 2026
Σύνδεσμοι
BibTeX
@article{kosmidis2026comprehensive,
title = {Comprehensive molecular profiling of advanced NSCLC in Greek patients:A prospective HeCOG study},
author = {Paris A. Kosmidis and Thanos Kosmidis and Kyriaki Papadopoulou and Nikolaos Korfiatis and Athanassios Vozikis and Sofia Lampaki and Panagiota Economopoulou and Elena Fountzila and Athina Christopoulou and E. Samantas and Anastasios Vagionas and Giannis Mountzios and Georgios Gkoumas and Nikolaos Tsoukalas and Ilias Athanasiadis and D. Bafaloukos and Chris Panopoulos and Margarita-Ioanna Koufaki and George Petrakis and Georgios Fountzilas and Helena Linardou},
url = {https://doi.org/10.1016/j.ctarc.2026.101310},
doi = {10.1016/j.ctarc.2026.101310},
year = {2026},
date = {2026-01-01},
journal = {Cancer Treatment and Research Communications},
volume = {48},
pages = {101310},
publisher = {Elsevier BV},
abstract = {BACKGROUND: We report for the first time the molecular landscape and outcome associations from the prospective CLIMEDIN trial in Greece. METHODS: Two hundred patients with newly diagnosed advanced NSCLC (March 2022-October 2023) were enrolled and randomized to standard-of-care education versus additional automated, adverse-event-targeted digital interventions. Within this study baseline testing (EGFR, ALK, PD-L1) was performed in all; 165 tumors underwent comprehensive NGS (Oncomine Comprehensive Assay v3). Primary endpoint was improvement in AEs/QoL; secondary endpoints included ORR, PFS and OS. Associations between genomic alterations and outcomes were explored. RESULTS: Median age was 68 years; 75% male; 52% current smokers; adenocarcinoma 68.5%. Most received chemo-immunotherapy (66%). At data cut-off (December 2025; reverse-Kaplan-Meier median follow-up 36.3 months), median PFS was 9.6 months and median OS was 15.2 months. Across 200 tumors, 495 pathogenic variants (PVs) were identified in 83 genes. Exploratory outcome analyses showed longer OS in EGFR-mutant disease (preserved under parsimonious multivariable adjustment) and a formal KRAS × smoking interaction for OS (interaction P = 0.011). CONCLUSIONS: In this cohort, the molecular profile mirrors other Caucasian series, with clinically relevant enrichment patterns for EGFR and KRAS. ECOG performance status and first line treatment were the dominant prognostic factors in this cohort. A novel KRAS and smoking interaction for overall survival warrants prospective validation.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}